Last reviewed · How we verify
SNA02-48
At a glance
| Generic name | SNA02-48 |
|---|---|
| Sponsor | Sinovac Life Sciences Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SNA02-48 Injection in Chinese Adult Participants (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SNA02-48 CI brief — competitive landscape report
- SNA02-48 updates RSS · CI watch RSS
- Sinovac Life Sciences Co., Ltd. portfolio CI